AbbVie Inc. (BCBA:ABBV)

Market Cap	557.47T
Revenue (ttm)	81.74T
Net Income (ttm)	3.22T
Shares Out	n/a
EPS (ttm)	1,809.89
PE Ratio	173.24
Forward PE	n/a
Dividend	584.54 (1.71%)
Ex-Dividend Date	Oct 15, 2025

Volume	2,639
Average Volume	948
Open	33,460
Previous Close	34,040
Day's Range	32,220 - 33,460
52-Week Range	18,325 - 38,540
Beta	n/a
RSI	45.73
Earnings Date	Oct 31, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: ABBV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD